It has been reported that H3K4me3 is significantly enriched at the SNCA promoter in the SN of PD patients, and the use of histone demethylase JARID1A can target the reduction of H3K4me3 levels in the SNCA promoter region and inhibit SNCA expression [27]. Here, KDM5A is linked to Parkinson disease.